Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Johnson & Johnson : J&J Chairman Weldon's Salary Cut To $1 Million After Stepping Down As CEO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/07/2012 | 11:51pm CEST
   By Peter Loftus 
   Of  
 

Johnson & Johnson (JNJ) Chairman William Weldon's annual base salary was reduced by nearly half to $1 million after he stepped down as chief executive last month, the company said Monday.

Weldon's previous annual base salary was set at $1.97 million for 2012, for his roles as both chairman and CEO, but with the expectation that J&J's board would consider the appropriate compensation for Weldon in his role as chairman only.

The decrease reflects that Weldon is no longer CEO, said spokesman Al Wasilewski.

On April 26, Alex Gorsky succeeded Weldon as CEO. Weldon is continuing as chairman and will remain an employee of the company, J&J said in a quarterly report filed with the Securities and Exchange Commission Monday.

J&J said in a previous SEC filing that in his role as chairman, Weldon will work closely with Gorsky to ensure a seamless leadership transition. During this time, all day-to-day management and operational responsibilities are being transferred to Gorsky.

Weldon will remain an employee but not a member of the J&J executive committee, which is the principal management group responsible for strategic operations and allocations of the resources of the company.

Weldon's main duties as chairman will include working with the board of directors, facilitating communication between the board and management, assisting Gorsky in business planning and strategy, representing the company before governmental and other organizations, and serving as chairman of the board's finance committee.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
01:45p Johnson & Johnson Wins Its First Talc-Ovarian Cancer Case
03/26 General Motors, Walmart, Pepsico and FX Networks also suspend Google ads
03/26 US featured innovative medical technologies at Riyadh event
03/25 AT&T, Verizon halt Google ads over extremist videos
03/24 JOHNSON & JOHNSON : Innovation launches Singapore QuickFire Challenge Competitio..
03/24 AT&T and Johnson & Johnson Pull Ads From YouTube
03/24 OPPORTUNISM KNOCKS : Marketers and media take on Google
03/24 JOHNSON & JOHNSON : EPREX Marketing Authorisation Extended to Include Treatment ..
03/24 YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/24 HOLOGIC : Global in-Vitro Diagnostics (IVD) Market-Danaher, Hologic, Alere, BD, ..
More news
Sector news : Pharmaceuticals - NEC
05:37pDJEU Clears Dow-DuPont Deal With Conditions -- 2nd Update
04:16pDJEU Clears Dow-DuPont Deal With Conditions -- Update
09:25a Chinese drug approval boosts AstraZeneca's lung cancer hopes
03/24 NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
11:21a Karyopharm's Selinexor Should Drive Substantial Growth
09:24a UPDATE : Portfolio123 Designer Low Volatility Portfolio
02:35a AMERICAN TOWER : Total Return Good With 10% -20% Growth Potential
12:27a 2 Tips For Mega-Cap Dividend Growth Investing
03/26 With Healthcare Now Off Trump's Agenda, It's Time To Dive Into The Sector
Advertisement
Financials ($)
Sales 2017 74 632 M
EBIT 2017 23 011 M
Net income 2017 17 928 M
Finance 2017 21 362 M
Yield 2017 2,67%
P/E ratio 2017 19,01
P/E ratio 2018 17,74
EV / Sales 2017 4,27x
EV / Sales 2018 4,01x
Capitalization 340 163 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 126 $
Spread / Average Target 0,65%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON8.91%340 163
ROCHE HOLDING LTD.8.73%219 545
PFIZER INC.4.68%202 474
NOVARTIS AG-0.94%195 096
MERCK & CO., INC.7.32%173 465
SANOFI7.76%115 582
More Results